SCHEMBL7050768

SCHEMBL7050768

CC(=O)O[C@@H](C)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I

nearest known ligand 0.70

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.70
SMN1; SMN2 Q16637 1/20 0.32
CYP2C19 P33261 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14334595 1.00 LMNA (0.70) LMNASMN1; SMN2CYP2C19HIF1A
SCHEMBL7764898 0.95 LMNA (0.64) LMNASMN1; SMN2
SCHEMBL9260881 0.94 LMNA (0.62) LMNA
SCHEMBL8978138 0.94 LMNA (0.62) LMNA
SCHEMBL20468079 0.93 LMNA (0.60) LMNASMN1; SMN2
SCHEMBL23633775 0.89 LMNA (0.59) LMNASMN1; SMN2
SCHEMBL21191482 0.88 LMNA (0.54) LMNA
SCHEMBL6835459 0.88 LMNA (0.53) LMNA
SCHEMBL6835457 0.88 LMNA (0.53) LMNA
SCHEMBL12845762 0.88 LMNA (0.53) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723709-B1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INT LTD (CH) 2015-09-09 EP claimed
US-8835672-B2 Manufacture of a triiodinated contrast agent HOVIONE INTER LIMITED (CH) 2014-09-16 US claimed
US-20140155648-A1 Manufacture of a Triiodinated Contrast Agent HOVIONE INTER LIMITED (CH) 2014-06-05 US claimed
US-6262303-B1 FROM THE COORRESPONDING DIACID CHLORIDE WITH 2-AMINO-1,3-PROPANEDIOL IN SOLVENT DIBRA S.P.A. (IT) 2001-07-17 US claimed
WO-2023117667-A1 PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODOISOPHTHALIC BISAMIDES BRACCO IMAGING SPA (IT) 2023-06-29 WO disclosed
EP-3369724-A1 PROCESS FOR THE PREPARATION OF IOPAMIDOL Bracco Imaging SPA (IT) 2018-09-05 EP disclosed
US-20170210692-A1 METHOD FOR THE PREPARATION OF (S)-2-ACETYLOXYPROPIONIC ACID AND DERIVATIVES THEREOF BRACCO IMAGING S.P.A. (IT) 2017-07-27 US disclosed
EP-2365963-B1 PROCESS FOR THE PREPARATION OF IODINATED CONTRAST AGENT BRACCO IMAGING SPA (IT) 2017-06-28 EP disclosed
US-20150329464-A1 CONTINUOUS PROCESS FOR THE PREPARATION OF (S)-2-ACETYLOXYPROPIONIC ACID CHLORIDE BRACCO IMAGING S.P.A. (IT) 2015-11-19 US disclosed
EP-2723709-B1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INT LTD (CH) 2015-09-09 EP disclosed
US-8835672-B2 Manufacture of a triiodinated contrast agent HOVIONE INTER LIMITED (CH) 2014-09-16 US disclosed
US-8835672-B2 Manufacture of a triiodinated contrast agent HOVIONE INTER LIMITED (CH) 2014-09-16 US disclosed
US-8624061-B2 Process for the preparation of iodinated contrast agent BRACCO IMAGING S.P.A. (IT) 2014-01-07 US disclosed
US-8624061-B2 Process for the preparation of iodinated contrast agent BRACCO IMAGING S.P.A. (IT) 2014-01-07 US disclosed
WO-2012175903-A1 MANUFACTURE OF A TRIIODINATED CONTRAST AGENT HOVIONE INTER. LTD (CH) 2012-12-27 WO disclosed
US-20110207960-A1 Process For The Preparation Of Iodinated Contrast Agent BRACCO IMAGING S.P.A. (IT) 2011-08-25 US disclosed
US-7368101-B2 Process for the preparation of iopamidol and the new intermediates therein BRACCO IMAGING S.P.A. (IT) 2008-05-06 US disclosed
US-7368101-B2 Process for the preparation of iopamidol and the new intermediates therein BRACCO IMAGING S.P.A. (IT) 2008-05-06 US disclosed
EP-1112247-B1 A PROCESS FOR THE PREPARATION OF S-N,N'-BIS 2-HYDROXY-1- (HYDROXYMETHYL) ETHYL]-5- (2-HYDROXY-1- OXOPROPYL) AMINO]-2,4,6- TRIIODO-1,3- BENZENEDICARBOXAMIDE BRACCO IMAGING SPA (IT) 2003-04-16 EP disclosed
US-6350908-B1 MULTISTAGE REACTION WITH AMIDATION OF ACYL HALIDES WITH AMINOALKANEDIOLS AND HYDROLYSIS BRACCO IMAGING S.P.A (IT) 2002-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329464-A1 CONTINUOUS PROCESS FOR THE PREPARATION OF (S)-2-ACETYLOXYPROPIONIC ACID CHLORIDE CLCN2, LPAR2, LPXN LMNA 1549/4885SMN1; SMN2 2284/4885CYP2C19 1463/4885
US-20110207960-A1 Process For The Preparation Of Iodinated Contrast Agent ITPR3, PPIP5K2, ITPR2 LMNA 1081/4885SMN1; SMN2 4307/4885CYP2C19 3306/4885
US-20170210692-A1 METHOD FOR THE PREPARATION OF (S)-2-ACETYLOXYPROPIONIC ACID AND DERIVATIVES THEREOF LDHA, ACACA, ADSL LMNA 467/4885SMN1; SMN2 2894/4885CYP2C19 1937/4885
US-20140155648-A1 Manufacture of a Triiodinated Contrast Agent SAT1, LYPLA2, AGPAT5 LMNA 2871/4885SMN1; SMN2 4778/4885CYP2C19 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.